Correlation of p16 expression and HPV type with survival in oropharyngeal squamous cell cancer

Liu, Sandy Z.; Zandberg, Dan P.; Schumaker, Lisa M.; Papadimitriou, John C.; Cullen, Kevin J.

doi:10.1016/j.oraloncology.2015.06.014

Cited by 45 publications

(33 citation statements)

References 56 publications

(94 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[12][13][14][15] Details on p16 testing can be found in Appendix 2 (available at www.cmaj.ca/lookup/suppl/doi :10.1503/cmaj.161379/-/DC1). p16 immunohistochemistry is a validated method to measure HPV status in oropharyngeal cancer.…”

Section: Data Collectionmentioning

confidence: 99%

Human papillomavirus in oropharyngeal cancer in Canada: analysis of 5 comprehensive cancer centres using multiple imputation

Habbous

Chu

Lau

et al. 2017

CMAJ

View full text Add to dashboard Cite

Section: Data Collectionmentioning

confidence: 99%

Human papillomavirus in oropharyngeal cancer in Canada: analysis of 5 comprehensive cancer centres using multiple imputation

Habbous

Chu

Lau

et al. 2017

CMAJ

View full text Add to dashboard Cite

“…12 In brief, p16 IHC was performed using commercially available antibodies (clone JC8; Santa Cruz Biotechnologies, Dallas, TX, USA) and scored for cytoplasmic and nuclear staining by a consensus of 2 blinded pathologists. Only tumor cells with moderate or high intensity were counted.…”

Section: P16mentioning

confidence: 99%

“…The most commonly used clinical tests are in situ hybridization to detect HPV DNA and p16 INK4a (p16) immunostaining. Overexpression of the protein p16 in HPV-transformed tumor cells is strongly correlated with the presence of oncogenic HPV and improved outcomes in HNSCC, [10][11][12] making it a useful surrogate marker for HPV-associated malignancy. In situ hybridization for HPV is highly specific for the specific genotypes tested (typically a pool of high-risk genotypes) but in studies in HNSCC, has frequently been found to lack sensitivity, resulting in unacceptable levels of false-negative results.…”

Section: Introductionmentioning

confidence: 99%

“…10,11,13,14 p16 immunostaining is sensitive but may be discordant with HPV status in a small number of cases. 12,15,16 Neither method provides the specific HPV genotype.…”

Section: Introductionmentioning

confidence: 99%

“…12 The linear array HPV (LAHPV; Roche Diagnostics) genotyping test has commonly been used in this context 12 and is effective in identifying 37 HPV genotypes (including all high-risk types) with high accuracy 18 in both preserved cytology and FFPE samples. Unfortunately, the assay is costly and low throughput.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Next-Generation Sequencing-Based HPV Genotyping Assay Validated in Formalin-Fixed, Paraffin-Embedded Oropharyngeal and Cervical Cancer Specimens

Ambulos

Schumaker

Mathias³

et al. 2016

J Biomol Tech

Self Cite

View full text Add to dashboard Cite

Available clinical human papilloma virus (HPV) diagnostics for head and neck cancer have limited sensitivity and/or fail to define the HPV genotype. Common HPV genotyping assays are costly and labor intensive. We sought to develop a next-generation sequencing (NGS)-based HPV genotyping assay that was sensitive enough to work on formalin-fixed paraffin-embedded (FFPE) samples. We developed an ion torrent NGS HPV genotyping assay using barcoded HPV PCR broad-spectrum general primers 5 + /6 + (BSGP)5 + /6 + . To validate genotype specificity and use in archived clinical FFPE tumor samples, we compared NGS HPV genotyping at 2 sequencing centers with typing by Roche Linear Array assay in 42 oropharyngeal and cervical cancer specimens representing 10 HPV genotypes, as well as HPV-negative cases. To demonstrate the detection of a broad range of HPV genotypes, we genotyped a cohort of 266 cervical cancers. A comparison of NGS genotyping of FFPE cancer specimens with genotyping by Linear Array showed concordant results in 34/37 samples (92%) at sequencing site 1 and 39/42 samples (93%) at sequencing site 2. Concordance between sites was 92%. Designed for use with 10 ng genomic DNA, the assay detected HPV using as little as 1.25 ng FFPE-derived genomic DNA. In 266 cervical cancer specimens, the NGS assay identified 20 different HPV genotypes, including all 13 carcinogenic genotypes. This novel NGS assay provides a sensitive and specific high-throughput method to detect and genotype HPV in a range of clinical specimens derived from FFPE with low per-sample cost.

show abstract

Human Papillomavirus Genotypes Conferring Poor Prognosis in Head and Neck Squamous Cell Carcinoma—Reply

2017

View full text Add to dashboard Cite

show abstract

Correlation of p16 expression and HPV type with survival in oropharyngeal squamous cell cancer

Cited by 45 publications

References 56 publications

Human papillomavirus in oropharyngeal cancer in Canada: analysis of 5 comprehensive cancer centres using multiple imputation

Human papillomavirus in oropharyngeal cancer in Canada: analysis of 5 comprehensive cancer centres using multiple imputation

Next-Generation Sequencing-Based HPV Genotyping Assay Validated in Formalin-Fixed, Paraffin-Embedded Oropharyngeal and Cervical Cancer Specimens

Human Papillomavirus Genotypes Conferring Poor Prognosis in Head and Neck Squamous Cell Carcinoma—Reply

Contact Info

Product

Resources

About